North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-04-01-01 Raloxifene
| Raloxifene Hydrochloride |
|
Formulary
|
|
 NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Not Approved) NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
|
Links
- British Menopause Society update on HRT supply
- MHRA Drug Safety Update (Aug 2019): Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping.
- NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Not Approved)
- NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
North East and North Cumbria ICB - Management of the Menopause- NTAG Endocrine System Recommendations